A study testing whether a new weekly shot from Lilly, tirzepatide, can calm gut inflammation.

Who can join

Adults 18 to 70, have ulcerative colitis, BMI 27+.

What you take

tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 2.8 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe.

Primary condition: Ulcerative Colitis. Also studied in: Obesity or Overweight.

Who can join, in detail

Key inclusion criteria

• Have had an established diagnosis of UC for >=3 months before baseline which includes endoscopic evidence of UC and a histopathology report that supports a diagnosis of UC.
• Have moderately to severely active UC as defined by a modified Mayo score (mMS) of 5 to 9 points and endoscopic subscore (ES) of 2 to 3 (confirmed by central review) within 21 days before baseline.
• Participants with a history of UC for greater than or equal to 8 years who have had a surveillance colonoscopy completed within 1 year prior to baseline must have documented negative results for colorectal dysplasia and cancer.
• Have obesity, [body mass index (BMI) 30 kilograms per meter squared (kg/m2)]
• Have overweight (BMI >=27 kg/m2 to <30 kg/m2) and in the presence of at least 1 of these weight-related comorbid conditions:

Key exclusion criteria

• Have a current diagnosis of:
• Crohn's disease
• inflammatory bowel disease (IBD) unclassified (formerly known as indeterminate colitis), or
• primary sclerosing cholangitis.
• Have had or will need bowel resection or intestinal or intra-abdominal surgery.

Where this study is enrolling

This trial has 37 US sites across 23 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2025-06-26. Expected completion: 2028-04. Last updated on ClinicalTrials.gov: 2026-05-12.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact